Key Highlights

  • bioAffinity Technologies will present CyPath Lung data at the NAVREF 2026 conference, including real-world case evaluations.
  • The presentations will highlight the active FlowPath Lung trial, which spans 2,000 subjects across VA and military facilities.
  • Prior data on small lung nodules showed 92% sensitivity, 87% specificity, and a 99% negative predictive value.
  • Distribution partner AvMEDICAL is supporting the company's push into federal healthcare markets.
  • Executive Leadership is emphasizing expansion within veteran and military health systems as a key growth channel.

Article

bioAffinity Technologies (NASDAQ: BIAF) has scheduled a series of presentations at the NAVREF 2026 conference to showcase clinical and veteran-oriented performance data for CyPath Lung, its non-invasive lung cancer detection test. The sessions will include real-world case evaluations alongside updates from the company's ongoing FlowPath Lung trial, a large-scale study spanning 2,000 subjects across VA and military healthcare facilities.

NAVREF, the National Association of Veterans' Research and Education Foundations, is a natural venue for this kind of data given the company's clear strategic emphasis on the veteran and military health system as a distribution channel. Veterans face elevated rates of lung cancer risk factors, including higher historical smoking rates and, in some cases, occupational and environmental exposures tied to military service, making early detection tools especially relevant to this population.

The clinical foundation supporting these presentations is meaningful. Prior data evaluating CyPath Lung's performance on small lung nodules — often the hardest cases to assess accurately — showed 92% sensitivity, 87% specificity, and a 99% negative predictive value. In practical terms, a negative predictive value that high means that when the test indicates a nodule is unlikely to be cancerous, physicians and patients can have a very high degree of confidence in that result, potentially sparing patients from unnecessary invasive follow-up procedures like biopsies.

The FlowPath Lung trial itself is the larger, forward-looking piece of the story. At 2,000 subjects and running specifically across VA and military facilities, it represents a substantial real-world validation effort that, if successful, would give the company a strong evidentiary base for expanding CyPath Lung's adoption throughout federal healthcare systems, which operate somewhat differently from the commercial insurance-driven market bioAffinity also serves.

Supporting that federal push is distribution partner AvMEDICAL, and company leadership has been vocal about federal market expansion as a strategic priority. Government and military health systems can offer a different kind of growth runway than commercial channels — often involving longer sales cycles but potentially more stable, large-scale adoption once a product is integrated into standard care pathways.

Investors will likely watch for interim or final FlowPath Lung data, along with any expanded distribution agreements or federal contract wins, as the next set of catalysts following the NAVREF 2026 presentations.